Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Bile Duct Cancer...
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Colorectal Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Metastatic Colorectal Cancer....
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According...
TQB-3804 by Chia Tai Tianqing Pharmaceutical Group for Non-Small Cell Lung Cancer: Likelihood of Approval
TQB-3804 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Non-Small Cell Lung...
TQB-2858 by Chia Tai Tianqing Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval
TQB-2858 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According...
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for B-Cell Non-Hodgkin Lymphoma....
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Hodgkin Lymphoma (B-Cell...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Esophageal Squamous Cell...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Biliary Tract Cancer: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Metastatic Biliary Tract...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Extrahepatic Bile Duct Cancer: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Extrahepatic Bile Duct...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Gallbladder Cancer: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Gallbladder Cancer. According...
TQB-2618 by Chia Tai Tianqing Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval
TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According...
Semaglutide by Chia Tai Tianqing Pharmaceutical Group for Type 2 Diabetes: Likelihood of Approval
Semaglutide is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase III for Type 2 Diabetes....
TQB-2868 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Pancreatic Cancer: Likelihood of Approval
TQB-2868 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Metastatic Pancreatic Cancer....
TQH-2722 by Chia Tai Tianqing Pharmaceutical Group for Nasal Polyps (Nasal Polyposis): Likelihood of Approval
TQH-2722 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Nasal Polyps (Nasal...
TQB-3525 by Chia Tai Tianqing Pharmaceutical Group for Cervical Cancer: Likelihood of Approval
TQB-3525 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Cervical Cancer. According...
TQB-3525 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Ovarian Cancer: Likelihood of Approval
TQB-3525 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Metastatic Ovarian Cancer....
TQH-2722 by Chia Tai Tianqing Pharmaceutical Group for Rhinosinusitis: Likelihood of Approval
TQH-2722 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Rhinosinusitis. According to...
TQH-2722 by Chia Tai Tianqing Pharmaceutical Group for Sinusitis: Likelihood of Approval
TQH-2722 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Sinusitis. According to...
TQB-3525 by Chia Tai Tianqing Pharmaceutical Group for Cervical Cancer: Likelihood of Approval
TQB-3525 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Cervical Cancer. According...